Mammary carcinoma in dogs: treatment, prognosis and clinical trials

Dogs · USA & Canada

Understanding mammary carcinoma

Canine mammary carcinoma is a malignant tumor of mammary tissue. These cancers range from relatively low-risk localized tumors to aggressive disease with lymph-node or lung spread. Tumor size, grade, lymphovascular invasion and stage are far more informative than the diagnosis name alone.

What does the prognosis look like?

Some dogs are cured by complete surgery, especially when the tumor is found small and pathology shows low-risk features. In one published group, the typical survival time was about 3 years when no tumor cells were seen in lymphatic vessels, compared with about 6 months when lymphatic invasion was present. Those figures are not universal, but they show why margins, grade, lymphatic invasion, lymph nodes and chest staging matter.

What matters next

Record how many mammary tumors are present and their sizes, and check the regional lymph nodes and lungs before assuming surgery is the whole treatment. After surgery, the pathology report—especially grade, margins and lymphovascular invasion—helps decide whether additional treatment is worth discussing.

Where are you now?

The mammary tumor is still present

Record the number and size of mammary tumors, assess the appropriate regional lymph nodes and decide the intended extent of surgery before operating. Staging first can prevent making the local plan in isolation.

Surgery has already been done

Use tumor size, grade, measured margins, lymphovascular invasion, and lymph-node status to decide whether surgery alone is reasonable or an oncology discussion is warranted.

A regional lymph node is positive

Nodal metastasis raises the risk of distant disease and can change staging and systemic-treatment recommendations. Confirm that the sampled node actually drains the affected mammary region.

There is metastatic, ulcerated, or recurrent disease

Systemic treatment and comfort become more important. Local surgery or radiation may still help selected painful, infected, ulcerated, or bleeding lesions when the expected benefit justifies recovery.

If you are waiting for oncology

Record every mammary nodule and its size, assess regional lymph nodes and complete chest staging when indicated. If surgery is planned, the extent should be decided intentionally rather than removing only the most obvious lump and sorting out stage later.

Questions to ask your oncologist

What are the tumor size, grade, lymphovascular-invasion and node findings?
What extent of surgery is appropriate for this pattern of disease?
Does this pathology justify systemic treatment or closer metastatic surveillance?

How the diagnosis may appear in the record

Record every mammary mass, not only the largest one. Useful pathology includes tumor type, grade, size, measured margins, lymphovascular invasion, and the result from the correct regional lymph node when sampled. Different nodules in the same dog can have different diagnoses.

Changes to watch for at home

Track growth, new nodules, redness, ulceration, discharge, bleeding, pain, or swelling of a regional node. Fever, rapidly spreading inflammation, uncontrolled bleeding, breathing difficulty, or inability to rest comfortably needs earlier care.

How it is usually treated

Surgery is the main treatment for localized mammary carcinoma. The amount of tissue removed depends on how many glands are involved and their location. Chemotherapy is considered selectively for higher-risk disease, especially when pathology shows aggressive features, lymph-node involvement or metastasis.

What can affect treatment choices

Tumor size and number, grade, lymphovascular invasion, lymph-node involvement, margins and distant spread are the main risk factors that determine whether surgery alone is likely to be enough.

Tests that may matter

Chest imaging and regional lymph-node assessment are commonly used for staging. Pathology after surgery should report tumor type, grade, margins and lymphovascular invasion when possible. Additional biomarker testing is most useful when it has a clear treatment or trial purpose.

Treatment options available now

6 options currently in our catalog.

Check eligibility

INSPIRE therapy for canine mammary carcinoma

NC State College of Veterinary Medicine · USA

Location

NC State Veterinary Hospital, 1052 William Moore Dr, Raleigh, NC 27607

Study details

Currently enrolling — official protocol lists enrollment through 2027-07-01

What is being offered: The direct NC State protocol lists enrollment through July 1, 2027. Candidates must have 1–2 discrete mammary tumors measuring 1–3 cm, weigh at least 30 lb, be previously spayed, have no metastasis, and be healthy enough for general anesthesia. INSPIRE uses electrical pulses to destroy tumor-cell membranes.

Who may qualify: Active tumor required; Measurable; Min tumor cm: 1; Max tumor cm: 3; Min weight lb: 30; Previously spayed; No metastasis

May not qualify if: Poor general health; Anesthesia contraindicated

Costs / coverage: 🟢 Fully funded. The protocol flyer lists cardiology and oncology consultations, bloodwork, thoracic radiographs, abdominal ultrasound and multiple CT scans as study benefits.

Contact: Jewels Darrow — 919-515-5090; jldarro2@ncsu.edu

Official study / enrollment information →

Evaluation of TLR agonist Z-007 in dogs with cancer

Cummings School of Veterinary Medicine, Tufts University · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Dog study of IV or intratumoral Z-007 for solid tumors including carcinomas, sarcomas and melanoma. Public criteria include a generally 2–7 cm repeat-biopsy-accessible tumor plus medical/laboratory requirements; no prior immunotherapy or autoimmune disease. Investigator prescreening required.

Who may qualify: Confirmed cancer diagnosis required; Min weight kg: 7; Measurable

May not qualify if: Prior immunotherapy

Costs / coverage: 🟡 Partially funded. Z-007 treatment through Day 63 and treatment of Z-007/biopsy-related side effects are covered; other owner costs should be confirmed with Tufts.

Contact: clinicaltrials@tufts.edu

Official study / enrollment information →

Palbociclib for selected progressive canine solid tumors

Auburn University College of Veterinary Medicine · USA

Location

Bailey Small Animal Teaching Hospital, 1220 Wire Rd, Auburn, AL 36849

Study details

Actively recruiting — confirmed on the institution’s current clinical-trials page

What is being offered: Dose-finding oral palbociclib treatment study for measurable progressive mammary carcinoma, SCC, histiocytic sarcoma, AGASACA or melanoma; prior cancer treatment is allowed if disease is progressing.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Measurable; Progressive

Costs / coverage: After owner-paid initial exam/screening, up to two months of trial treatment including biopsy, rechecks, bloodwork and chemotherapy are funded.

Contact: Auburn Oncology Service — (334) 844-4690; onco@auburn.edu

Official study / enrollment information →

Compassionate-Use Protocol for Advanced Non-Resectable Tumors

UT Southwestern Veterinary Research and Oncology Clinic · USA

Location

Veterinary Research and Oncology Clinic, 5801 Forest Park Rd, Dallas, TX 75235

Study details

Current

What is being offered: Investigational therapy, chemotherapy, immunotherapy and combination approaches under a prospective compassionate-use protocol

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Min weight kg exclusive: 2.5; min expected survival weeks: 3 weeks; Adequate organ function

May not qualify if: Severe systemic disease

Costs / coverage: ⚪ Owner-paid. The protocol brochure states that owners fully pay for the study, although possible subsidies may be available.

Contact: Paige Neumann, Research Study Coordinator — 214-645-6221; VROC@UTSouthwestern.edu

Official study / enrollment information →

Kubanda veterinary cryotherapy for canine mammary cancer

Johns Hopkins Center for Image-Guided Animal Therapy (CIGAT) / Kubanda Cryotherapy · USA

Location

Johns Hopkins CIGAT, 600 N Wolfe St, Park 311, Baltimore, MD 21287

Study details

Now recruiting — Phase IB trial listed on the current Johns Hopkins CIGAT clinical-trials page

What is being offered: Current institution master states recruitment for Phase IB Kubanda mammary cryotherapy. Individual official flyer requires histopathologic mammary cancer, no prior treatment of the lump or chemotherapy for other cancers, and systemic fitness. Cryotherapy is followed a few weeks later by surgical mass removal. Other investigational treatment, concurrent study enrollment and life-threatening medical/immunosuppressive illnesses exclude entry. Detailed team screening remains required.

Who may qualify: Active tumor required; Confirmed cancer diagnosis required

May not qualify if: Prior chemo

Costs / coverage: 🟡 Partially funded. Owners pay for diagnosis and staging; the primary study flyer states that cryotherapy and subsequent mass removal are fully funded, with follow-up assessments at no owner cost. Unrelated care and travel coverage are not stated.

Contact: Kubanda Cryotherapy / Johns Hopkins CIGAT — contact through the official clinical-trials page

Official study / enrollment information →

Single-fraction SABR for progressive canine lung metastases

Tufts Cummings School of Veterinary Medicine · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Single highly focused radiation dose for dogs with 2–10 progressive pulmonary metastatic nodules. The primary tumor, regional nodes and any non-pulmonary metastases must already be controlled; progression must be documented over 6–8 weeks, and all progressive lung lesions at least 5 mm must be safely treatable. Prior systemic therapy is allowed; cytotoxic chemotherapy pauses around SABR, while tolerated targeted therapy or immunotherapy may continue with radiation-oncologist approval. Tufts prescreening is required.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Metastatic; Measurable lung metastases; Planned radiation

Costs / coverage: 🟡 Partially funded. The study covers SABR, the one-month follow-up, adverse-event rechecks related to lung toxicity, and up to $860 toward the 2–3-month CT visit. Owners pay pre-enrollment bloodwork, chest imaging, treatment-planning CT, and diagnostic confirmation.

Contact: Tufts Clinical Trials Office — clinicaltrials@tufts.edu; owner and referring-veterinarian prescreening questionnaires on the official page

Official study / enrollment information →